Alpha-9 Oncology Inc. is a clinical stage radiopharmaceutical company developing differentiated and highly targeted radiopharmaceuticals with the potential to meaningfully improve the treatment of people living with cancer. Applying proprietary technologies and deep foundational expertise, Alpha-9 is on the forefront of engineering bespoke radiopharmaceuticals that are optimized to selectively deliver radiation to tumor sites while minimizing off-target effects. Alpha-9 is advancing a robust pipeline of novel radiopharmaceuticals with a systematic approach to molecule design that offers broad potential for expansion into several validated oncology targets.

Key Contact

Funding Events

Date	Amount	Type	Investors	Valuation
10/23/24	$175,000,000	Series C	A16z abrdn Ascenta Capital BVF Partners Delos Capital Digitalis Ventures Frazier Life Sciences General Catalyst Partners Janus Henderson Investors Lightspeed Venture Partners Longitude Capital Lumira Ventures Nextech Invest RA Capital Management Samsara BioCapital	undisclosed